Cabozantinib shows significant activity in the first line for differentiated thyroid cancer

American Society for Radiation Oncology (ASTRO)SCOTTSDALE, Ariz., Feb. 13, 2018 /PRNewswire-USNewswire/ -- Results of a new phase II clinical trial indicate that cabozantinib offers an active therapy option for patients with differentiated thyroid cancer (DTC) that has progressed following surgery and treatment with radioactive iodine...

Leave a comment

Your email address will not be published.